CD4 and leishmaniasis: While a human vaccine for leishmaniasis remains unavailable, successful examples of experimental vaccines suggest that inducing protective, long-lived skin CD4+ TRM cells, independent of persistent parasites, might be a promising approach for future vaccine development and evaluating the protective efficacy induced by such vaccination (213).